{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:32:10Z","timestamp":1790062330737,"version":"4.0.1"},"reference-count":37,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,10,24]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study of two pivotal phase III studies: MEASURE 1 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01358175\">NCT01358175<\/jats:ext-link>) and MEASURE 2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01649375\">NCT01649375<\/jats:ext-link>).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This post hoc analysis pooled data from all patients with available baseline CRP in the two studies who received subcutaneous secukinumab 150 \u2009mg (approved dose; N=197) or placebo (N=195). Assessed efficacy endpoints included Assessments of SpondyloArthritis international Society (ASAS)20\/40, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI50, AS Disease Activity Score inactive disease and ASAS partial remission among patients grouped by baseline CRP based on central laboratory cut-off &lt;5 \u2009mg\/L (normal) or \u22655 \u2009mg\/L (elevated) and a cut-off &lt;10 \u2009mg\/L or \u226510 \u2009mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, 36.5% (143\/392) patients had normal and 63.5% (249\/392) had elevated CRP. At week 16, ASAS20\/40 response rates were higher for secukinumab versus placebo in normal (56.9%\/34.7% vs 28.2%\/7.0%; p&lt;0.01\/p&lt;0.001) and in elevated (63.2%\/42.4% vs 29.0%\/15.3%; both p&lt;0.0001) CRP groups. Improvement was reported for all outcomes (p&lt;0.05) in both groups, except for ASAS partial remission in the normal CRP group, where a numerical difference 12.5% vs 2.8%, p=0.07) was observed. Similar trends of improvement were observed in the &lt;10 \u2009and \u226510 \u2009mg\/L groups across all efficacy outcomes at week 16. Treatment responses to secukinumab in all CRP groups further improved over 156 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Secukinumab 150 \u2009mg demonstrated rapid and sustained efficacy in patients with AS irrespective of baseline CRP, with greater magnitude of response in patients with more elevated CRP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000749","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:22:29Z","timestamp":1542867749000},"page":"e000749","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":41,"title":["Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies"],"prefix":"10.1136","volume":"4","clinical-trial-number":[{"clinical-trial-number":"nct01358175","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01649375","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01358175","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01649375","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"J\u00fcrgen","family":"Braun","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"University of Amsterdam and Atrium Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[{"name":"Paris Descartes University, Department of Rheumatology -H\u00f4pital Cochin, Assistance Publique - H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhard","family":"Quebe-Fehling","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal K","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MEASURE 1 and MEASURE 2 study groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"key":"2025090313015733000_4.2.e000749.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"2025090313015733000_4.2.e000749.2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9771-9"},{"key":"2025090313015733000_4.2.e000749.3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10067-015-2949-3","article-title":"Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis","volume":"34","author":"Reveille","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2025090313015733000_4.2.e000749.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2025090313015733000_4.2.e000749.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147744"},{"key":"2025090313015733000_4.2.e000749.6","first-page":"1751","article-title":"Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept","volume":"32","author":"Davis","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090313015733000_4.2.e000749.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025090313015733000_4.2.e000749.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24838"},{"key":"2025090313015733000_4.2.e000749.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2025090313015733000_4.2.e000749.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204317"},{"key":"2025090313015733000_4.2.e000749.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2025090313015733000_4.2.e000749.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2025090313015733000_4.2.e000749.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160003"},{"key":"2025090313015733000_4.2.e000749.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073098"},{"key":"2025090313015733000_4.2.e000749.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2025090313015733000_4.2.e000749.16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/1756-185X.13094","article-title":"Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies","volume":"20","author":"Wei","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025090313015733000_4.2.e000749.17","first-page":"50","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313015733000_4.2.e000749.18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000592","article-title":"Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2","volume":"3","author":"Marzo-Ortega","year":"2017","journal-title":"RMD Open"},{"key":"2025090313015733000_4.2.e000749.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090313015733000_4.2.e000749.20","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090313015733000_4.2.e000749.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208593"},{"key":"2025090313015733000_4.2.e000749.22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/acr.23092","article-title":"Early disease activity or clinical response as predictors of long-term outcomes with certolizumab pegol in axial spondyloarthritis or psoriatic arthritis","volume":"69","author":"van der Heijde","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090313015733000_4.2.e000749.23","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(87)90129-3"},{"key":"2025090313015733000_4.2.e000749.24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1998)12:3<137::AID-JCLA2>3.0.CO;2-6"},{"key":"2025090313015733000_4.2.e000749.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"2025090313015733000_4.2.e000749.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2025090313015733000_4.2.e000749.27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040758"},{"key":"2025090313015733000_4.2.e000749.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090313015733000_4.2.e000749.29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13075-016-1200-1","article-title":"Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study","volume":"18","author":"Inman","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313015733000_4.2.e000749.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev267"},{"key":"2025090313015733000_4.2.e000749.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090313015733000_4.2.e000749.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep422"},{"key":"2025090313015733000_4.2.e000749.33","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"2025090313015733000_4.2.e000749.34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes057"},{"key":"2025090313015733000_4.2.e000749.35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Reumatol Clin"},{"key":"2025090313015733000_4.2.e000749.36","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313015733000_4.2.e000749.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141278"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:02:04Z","timestamp":1756929724000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,11,21]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/rmdopen-2018-000749"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000749","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}